MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says

MT Newswires Live03-30

MoonLake Immunotherapeutics (MLTX) reported 40-week data from its phase 3 VELA-1 and VELA-2 studies of sonelokimab to treat hidradenitis suppurativa that continue to support efficacy comparable to bimekizumab, Wedbush Securities said in a Monday note.

Wedbush said updated results presented at the American Academy of Dermatology Annual Meeting showed continued efficacy improvement beyond week 16, with response levels broadly comparable to bimekizumab from UCB's phase 3 trials at 48 weeks.

According to the report, the new VELA-2 data showed patients switching from placebo to sonelokimab improved rapidly within four weeks, helping explain earlier HiSCR75 variability and reinforcing the drug's underlying efficacy.

The analysts said improvements in patient-reported outcomes and pain reduction aligned with lower lesion counts and limited placebo effects, supporting the therapeutic benefit of sonelokimab in hidradenitis suppurativa.

The company plans to submit a biologics license application for sonelokimab in hidradenitis suppurativa by late Q3 2026 and may seek priority review after a pre-BLA meeting with regulators, Wedbush added.

The firm maintained its outperform rating on the stock with a $34 price target.

Price: 16.90, Change: -0.42, Percent Change: -2.40

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623293344?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 23:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623293344","market":"fut","top_or_hot":-1,"title":"MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> (MLTX) reported 40-week data from its phase 3 VELA-1 and VELA-2 studies of sonelokimab to treat hidradenitis suppurativa that continue to support efficacy comparable to bimekizumab, Wedbush Securities said in a Monday note.</p><p>Wedbush said updated results presented at the American Academy of Dermatology Annual Meeting showed continued efficacy improvement beyond week 16, with response levels broadly comparable to bimekizumab from UCB's phase 3 trials at 48 weeks.</p><p>According to the report, the new VELA-2 data showed patients switching from placebo to sonelokimab improved rapidly within four weeks, helping explain earlier HiSCR75 variability and reinforcing the drug's underlying efficacy.</p><p>The analysts said improvements in patient-reported outcomes and pain reduction aligned with lower lesion counts and limited placebo effects, supporting the therapeutic benefit of sonelokimab in hidradenitis suppurativa.</p><p>The company plans to submit a biologics license application for sonelokimab in hidradenitis suppurativa by late Q3 2026 and may seek priority review after a pre-BLA meeting with regulators, Wedbush added.</p><p>The firm maintained its outperform rating on the stock with a $34 price target.</p><p>Price: 16.90, Change: -0.42, Percent Change: -2.40</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-30 23:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> (MLTX) reported 40-week data from its phase 3 VELA-1 and VELA-2 studies of sonelokimab to treat hidradenitis suppurativa that continue to support efficacy comparable to bimekizumab, Wedbush Securities said in a Monday note.</p><p>Wedbush said updated results presented at the American Academy of Dermatology Annual Meeting showed continued efficacy improvement beyond week 16, with response levels broadly comparable to bimekizumab from UCB's phase 3 trials at 48 weeks.</p><p>According to the report, the new VELA-2 data showed patients switching from placebo to sonelokimab improved rapidly within four weeks, helping explain earlier HiSCR75 variability and reinforcing the drug's underlying efficacy.</p><p>The analysts said improvements in patient-reported outcomes and pain reduction aligned with lower lesion counts and limited placebo effects, supporting the therapeutic benefit of sonelokimab in hidradenitis suppurativa.</p><p>The company plans to submit a biologics license application for sonelokimab in hidradenitis suppurativa by late Q3 2026 and may seek priority review after a pre-BLA meeting with regulators, Wedbush added.</p><p>The firm maintained its outperform rating on the stock with a $34 price target.</p><p>Price: 16.90, Change: -0.42, Percent Change: -2.40</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MLTX","symbol_name":"MoonLake Immunotherapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2623293344","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623293344","pubTimestamp":1774884909,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"MoonLake Immunotherapeutics  reported 40-week data from its phase 3 VELA-1 and VELA-2 studies of sonelokimab to treat hidradenitis suppurativa that continue to support efficacy comparable to bimekizumab, Wedbush Securities said in a Monday note.Wedbush said updated results presented at the American Academy of Dermatology Annual Meeting showed continued efficacy improvement beyond week 16, with response levels broadly comparable to bimekizumab from UCB's phase 3 trials at 48 weeks.According to the report, the new VELA-2 data showed patients switching from placebo to sonelokimab improved rapidly within four weeks, helping explain earlier HiSCR75 variability and reinforcing the drug's underlying efficacy.The analysts said improvements in patient-reported outcomes and pain reduction aligned with lower lesion counts and limited placebo effects, supporting the therapeutic benefit of sonelokimab in hidradenitis suppurativa.The company plans to submit a biologics license application for sonelo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MLTX":"MoonLake Immunotherapeutics","BK4139":"生物科技"},"translate_title":"Wedbush表示，MoonLake试验数据继续支持Sonelokimab治疗化脓性汗腺炎的疗效","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLTX":1},"content_text":"MoonLake Immunotherapeutics (MLTX) reported 40-week data from its phase 3 VELA-1 and VELA-2 studies of sonelokimab to treat hidradenitis suppurativa that continue to support efficacy comparable to bimekizumab, Wedbush Securities said in a Monday note.Wedbush said updated results presented at the American Academy of Dermatology Annual Meeting showed continued efficacy improvement beyond week 16, with response levels broadly comparable to bimekizumab from UCB's phase 3 trials at 48 weeks.According to the report, the new VELA-2 data showed patients switching from placebo to sonelokimab improved rapidly within four weeks, helping explain earlier HiSCR75 variability and reinforcing the drug's underlying efficacy.The analysts said improvements in patient-reported outcomes and pain reduction aligned with lower lesion counts and limited placebo effects, supporting the therapeutic benefit of sonelokimab in hidradenitis suppurativa.The company plans to submit a biologics license application for sonelokimab in hidradenitis suppurativa by late Q3 2026 and may seek priority review after a pre-BLA meeting with regulators, Wedbush added.The firm maintained its outperform rating on the stock with a $34 price target.Price: 16.90, Change: -0.42, Percent Change: -2.40","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623293344","isCrawlerRequest":true}